Cells communicate with protein networks called signaling pathways. One common pathway in cancer includes a protein called mTOR. mTOR acts in two complexes, named mTORC1 and mTORC2. Each complex controls different cell functions.
Most current drugs affect both mTORC1 and mTORC2. The researchers say blocking mTORC1 can make cancer cells more resistant to chemotherapy, so that can limit drug benefit.
The new study reports that it may be possible to block only mTORC2. That selective approach could stop cancer growth signals without turning on survival pathways. Scientists are now working on drug designs based on this idea.
Difficult words
- pathway — series of actions that send a signalsignaling pathways
- complex — group of proteins that work togethercomplexes
- block — stop something from happening or movingblocking
- resistant — able to survive or not be harmed
- chemotherapy — treatment using drugs to kill cancer
- selective — affecting only one specific part or target
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why might scientists want drugs that are selective for one complex?
- How could stopping growth signals help cancer treatment?
- Have you heard of chemotherapy before? What do you know about it?
Related articles
Study finds Abbott-Bioline malaria test gives many false negatives
A study on the Thailand–Myanmar border found the Abbott-Bioline rapid malaria test missed many infections. Researchers call it “not fit for purpose”; WHO and the manufacturer are reviewing the test and further studies are under way.
Most US drug trials do not mirror racial and ethnic diversity
A study of pivotal trials used to approve new drugs found only a small share reflect the United States racial and ethnic makeup. The review shows underrepresentation of Black and Hispanic people and urges more diversity earlier in development.
Clock disruption speeds breast cancer in models
New research finds that repeating disruption of the body’s 24-hour clock changes breast tissue, weakens immune defenses and leads to faster, more aggressive breast cancer in experimental models. The study links altered light–dark schedules to worse outcomes.
